Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

TESLA

Rationale for TESLA and results

Rationale for TESLA and results

Low density lipoprotein cholesterol (LDL-C) can be significantly reduced in patients with a serious genetic disorder – homozygous familial hypercholesterolaemia (FH) – when a PCSK9 inhibitor evolocumab is added to statins and other lipid-lowering medications. Professor Frederick Raal explains the results of the TESLA study.

read more »
PlayImplications from TESLA for FH management

Implications from TESLA for FH management

The investigational PCSK9 inhibitor evolocumab, promises to be an important new treatment for a rare but serious genetic disorder, homozygous familial hypercholesterolaemia, according to one of the investigators in the TESLA study, Professor Frederick Raal.

read more »
TESLA in brief

TESLA in brief

TESLA was a randomised, double-blind, placebo-controlled trial of the PCSK9 inhibitor, evolocumab, in 50 patients (49 received treatment) with homozygous FH (mean LDL-C at baseline 9.0 mmol/L). All were on statins and 91% also received ezetimibe. LDL receptor mutations were identified in 45 (92%) patients;…

read more »
EAS Madrid: What made the clinical news about PCSK9?

EAS Madrid: What made the clinical news about PCSK9?

TESLA: PCSK9 inhibition effective in homozygous FH Phase III TESLA study shows that treatment with the PCKS9 monoclonal antibody inhibitor evolocumab significantly lowered LDL-C by 31% at week 12 in patients with homozygous FH (HoFH) receiving intensive statin treatment and other lipid-modifying therapy. For the…

read more »
PlayImplications from TESLA and early TAUSSIG studies with evolocumab

Implications from TESLA and early TAUSSIG studies with evolocumab

Results of clinical trials of the investigational therapy – evolocumab, a PCSK9 inhibitor will potentially change care of patients at a high risk of cardiovascular disease (heart attacks), by reducing their very high low density lipoprotein cholesterol (LDL-C) levels. The Forum talks to Professor Gerald…

read more »
PlayRationale for TESLA and results

Rationale for TESLA and results

Low density lipoprotein cholesterol (LDL-C) can be significantly reduced in patients with a serious genetic disorder – homozygous familial hypercholesterolaemia (FH) – when a PCSK9 inhibitor evolocumab is added to statins and other lipid-lowering medications. Professor Frederick Raal explains the results of the TESLA study.

read more »
TESLA

TESLA

Trial TESLA-Pilot (Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities) Aim To evaluate the efficacy and safety of evolocumab in patients with homozygous familial hypercholesterolaemia Study design Open-label, single-arm, multicentre, dose scheduling pilot studySubcutaneous evolocumab, 420 mg every 4 weeks for ≥12 weeks,…

read more »